Results 1 to 20 of 27
Page 1 of 2  Next >
TypeTitleAuthor(s)YearViews
A new concept of continental construction in the Central Asian Orogenic Belt: (Compared to actualistic examples from the Western Pacific)Safonova, I; Seltmann, E; Kröner, A; Gladkochub, D; Schulmann, K; Xiao, W; Kim, J; Komiya, T; Sun, M2011264
 
Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylaseDu, J; Zhou, Y; Su, X; Yu, JJ; Khan, S; Jiang, H; Kim, J; Woo, J; Kim, JH; Choi, BH; He, B; Chen, W; Zhang, S; Cerione, RA; Auwerx, J; Hao, Q; Lin, H2011193
 
In vitro remineralization of severely compromised bonded dentinMai, S; Kim, YK; Kim, J; Yiu, CKY; Ling, J; Pashley, DH; Tay, FR2010140
 
Quantum size effects on the work function of metallic thin film nanostructuresKim, J; Qin, S; Yao, W; Niu, Q; Chou, MY; Shih, CK2010587
 
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant diseaseYuen, MF; Han, KH; Um, SH; Yoon, SK; Kim, HR; Kim, J; Kim, CR; Lai, CL201097
 
Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancerYang, W; Cai, Q; Lui, VWY; Everley, PA; Kim, J; Bhola, N; Quesnelle, KM; Zetter, BR; Steen, H; Freeman, MR; Grandis, JR201019
 
An all-in-one adhesive does not etch beyond hybrid layersKim, J; Mai, S; Carrilho, MR; Yiu, CKY; Pashley, DH; Tay, FR2010218
 
PyongyangRoberts, PM; Kim, J201038
 
Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and miceYuen, MF; Lee, SH; Kang, HM; Chung, RK; Kim, J; Ngai, V; Lai, CL2009461
 
Clock synchronization in wireless sensor networks: An overviewRhee, IK; Lee, J; Kim, J; Serpedin, E; Wu, YC2009450
 
The IPO Derby: Are there consistent losers and winners on this track?Chan, K; Cooney, J; Kim, J; Singh, A2008166
 
Are there long-run implications of analyst coverage for IPOs?Chan, K; Bradley, D; Kim, J; Singh, A2008195
 
An MTT-based method for quantification of periodontal ligament cell viabilityKim, E; Jeon, IS; Kim, JW; Kim, J; Jung, HS; Lee, SJ200759
 
Molecular phylogenetic relationships of Asiatic black bear (Ursus thibetanus) populations in East Asia and its conservation implicationsMin, M; Hong, Y; Park, H; Kim, Y; Kim, Y; Han, S; Smith, GJ; Renzhu, P; Hwang, M; Myslenkov, A; Voloshina, IV; Kim, C; Kim, J; Lee, H2006154
 
Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBVLai, CL; Han, KH; Yoon, SK; Um, SH; Yuen, MF; Kim, HS; Kim, HR; Chung, HC; Kim, CR; Hsyu, P; Averett, D; Worland, S; Kim, J2006207
 
A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis BYuen, MF; Kim, J; Kim, CR; Ngai, V; Yuen, JCH; Min, C; Kang, HM; Shin, BS; Yoo, SD; Lai, CL2006179
 
Interim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infectionYuen, RMF; Kim, J; Wong, DKH; Ngai, WS; Yuen, JCH; Lai, CL2004142
 
Interim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection.Yuen, RMF; Kim, J; Wong, DKH; Ngai, WS; Yuen, JCH; Lai, CL2004132
 
Phase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection.Yuen, RMF; Kim, J; Averett, D; Wong, DKH; Kim, CR; Kerr, B; Ngai, WS; Yuen, JCH; Lai, CL2004189
 
A phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in patients with chronic hepatitis B infectionYuen, RMF; Kim, J; Wong, DKH; Ngai, WS; Yuen, JCH; Lai, CL2003159
 
Page 1 of 2  Next >
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download